Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Hannah L RushLaura MurphyAlicia K MorgansNoel W ClarkeAdrian D CookGerhardt AttardArchie MacnairDavid P DearnaleyChristopher C ParkerJ Martin RussellSilke Gillessen SommerDavid J MathesonRobin MillmanChristopher D BrawleyCheryl PughJacob S TanguayRobert J JonesJohn WagstaffSarah RudmanJoe M O'SullivanJoanna GaleAlison Jane BirtleAndrew S ProtheroeEmma GrayCarla PernaShaun TolanNeil McPhailZaf I MalikSalil VengalilDavid FackrellPeter J HoskinMatthew Robert SydesSimon ChowdhuryDuncan C GilbertMahesh K B ParmarNicholas D JamesRuth E LangleyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Patient-reported QOL was superior for patients allocated to receive AAP + SOC, compared with docetaxel + SOC over a 2-year period, narrowly missing the predefined value for clinical significance. Patients receiving AAP + SOC reported clinically meaningful higher global-QOL scores throughout the first year following random assignment.